Literature DB >> 16437272

Predictive factors of coexisting cancer in Barrett's high-grade dysplasia.

C Tharavej1, J A Hagen, J H Peters, G Portale, J Lipham, S R DeMeester, C G Bremner, T R DeMeester.   

Abstract

BACKGROUND: Identification of high-grade dysplasia (HGD) in Barrett's esophagus has been considered an indication for esophagectomy because of the high risk for coexisting cancer. However, rigorous endoscopic surveillance programs recently have been recommended, reserving esophagectomy for patients whose cancer is identified on biopsy. This approach risks continued surveillance for patients who already have cancer unless reliable markers for the presence of occult cancer are identified. This study aimed to determine the endoscopic, histologic, and demographic features associated with the presence of occult cancer in patients with HGD.
METHODS: Endoscopic, histologic, and demographic findings for 31 patients who underwent esophagectomy for HGD were reviewed. The presence of an ulcer, nodule, stricture, or raised area on preoperative endoscopy was noted. The results of endoscopic biopsies taken before resection every 1 to 2 cm along the Barrett's segment were reviewed. The HGD was categorized as unilevel if the dysplasia was limited to one level of biopsy and as multilevel if more than one level was involved. Patients were divided into two groups according to the presence or absence of cancer in the resected specimens, and these variables were compared.
RESULTS: The prevalence of coexisting cancer in patients with HGD was 45% (14/31). Of the 31 patients in this study, 9 had a visible lesion. Cancer was found in the resected specimens from 7 (78%) of 9 patients with a visible lesion and 7 (32%) of 22 patients without a visible lesion (p = 0.019). Of 22 patients without a visible lesion, 10 had multilevel and 12 had unilevel HGD. The findings showed that 6 (60%) of 10 patients with multilevel HGD and 1 (8.3%) of 12 patients with unilevel HGD had cancer in the resected esophagus (p = 0.009).
CONCLUSION: For patients with HGD, a lesion visible on endoscopy and/or HGD at multiple biopsy levels is associated with an increased risk for coexisting cancer. These patients should be considered for early esophagectomy.

Entities:  

Mesh:

Year:  2006        PMID: 16437272     DOI: 10.1007/s00464-005-0255-x

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  26 in total

1.  Oesophageal resection for high-grade dysplasia in Barrett's oesophagus.

Authors:  G Zaninotto; A R Parenti; A Ruol; M Costantini; S Merigliano; E Ancona
Journal:  Br J Surg       Date:  2000-08       Impact factor: 6.939

Review 2.  High grade dysplasia: surveillance, mucosal ablation, or resection?

Authors:  Robert J Korst; Nasser K Altorki
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

Review 3.  A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop.

Authors:  Prateek Sharma; Kenneth McQuaid; John Dent; M Brian Fennerty; Richard Sampliner; Stuart Spechler; Alan Cameron; Douglas Corley; Gary Falk; John Goldblum; John Hunter; Janusz Jankowski; Lars Lundell; Brian Reid; Nicholas J Shaheen; Amnon Sonnenberg; Kenneth Wang; Wilfred Weinstein
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

4.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

5.  Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy.

Authors:  J J Nigro; J A Hagen; T R DeMeester; S R DeMeester; J Theisen; J H Peters; M Kiyabu
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

6.  Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

Authors:  A P Weston; A S Badr; R S Hassanein
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

7.  Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus.

Authors:  R E Rudolph; T L Vaughan; B E Storer; R C Haggitt; P S Rabinovitch; D S Levine; B J Reid
Journal:  Ann Intern Med       Date:  2000-04-18       Impact factor: 25.391

8.  Barrett's esophagus with high grade dysplasia: surgical results and long-term outcome--an update.

Authors:  Elaine E Tseng; T T Wu; Charles J Yeo; Richard F Heitmiller
Journal:  J Gastrointest Surg       Date:  2003-02       Impact factor: 3.452

9.  High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy.

Authors:  James R Headrick; Francis C Nichols; Daniel L Miller; Mark S Allen; Victor F Trastek; Claude Deschamps; Cathy D Schleck; Ann M Thompson; Peter C Pairolero
Journal:  Ann Thorac Surg       Date:  2002-06       Impact factor: 4.330

10.  Barrett's esophagus. Comparison of benign and malignant cases.

Authors:  D B Skinner; B C Walther; R H Riddell; H Schmidt; C Iascone; T R DeMeester
Journal:  Ann Surg       Date:  1983-10       Impact factor: 12.969

View more
  19 in total

Review 1.  Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?

Authors:  Vani J A Konda; Mark K Ferguson
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

2.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

Review 3.  Management of high-grade dysplasia.

Authors:  Francesco Palazzo; Piero M Fisichella; Marco G Patti
Journal:  Curr Gastroenterol Rep       Date:  2008-06

Review 4.  SSAT controversies intramucosal esophageal cancer and high-grade dysplasia: which treatment? Surgical therapy: improved outcomes and piece of mind.

Authors:  Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2009-03-18       Impact factor: 3.452

5.  Low risk of prevalent submucosal invasive cancer among patients undergoing esophagectomy for treatment of Barrett's esophagus with high grade dysplasia.

Authors:  Vani Ja Konda; Irving Waxman
Journal:  J Gastrointest Oncol       Date:  2011-03

6.  Low prevalence of invasive adenocarcinoma and occult cancer on esophageal resection for Barrett's esophagus with high-grade dysplasia: Evidence for conservative management.

Authors:  Deepa T Patil; Thomas P Plesec; John R Goldblum
Journal:  J Gastrointest Oncol       Date:  2011-03

Review 7.  How Should We Report Endoscopic Results in Patient's with Barrett's Esophagus?

Authors:  Venkata Subhash Gorrepati; Prateek Sharma
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

8.  Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.

Authors:  Aaron J Small; James L Araujo; Cadman L Leggett; Aaron H Mendelson; Anant Agarwalla; Julian A Abrams; Charles J Lightdale; Timothy C Wang; Prasad G Iyer; Kenneth K Wang; Anil K Rustgi; Gregory G Ginsberg; Kimberly A Forde; Phyllis A Gimotty; James D Lewis; Gary W Falk; Meenakshi Bewtra
Journal:  Gastroenterology       Date:  2015-04-24       Impact factor: 22.682

Review 9.  Mucosal ablation of Barrett esophagus.

Authors:  Irving Waxman; Vani J A Konda
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-02       Impact factor: 46.802

Review 10.  Management controversies in Barrett's oesophagus.

Authors:  L Max Almond; Hugh Barr
Journal:  J Gastroenterol       Date:  2013-06-05       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.